

bidity and mortality of cardiovascular disease and its risk factors in a community living in the town of Hisayama in Japan (Katsuki, 1966; Arima *et al.*, 2003). At the initial screening in 1961, 1621 subjects aged 40 years or older were registered as a cohort population; this group of subjects included almost 90% of the total population of this age group (Fig. 1). Of the initial cohort population, 1309 had died by 2001, and of these, 1033 (78.9%) underwent autopsy examination. In the autopsy cases, tissue samples of the main organs, such as the brain, heart, lung, liver, spleen, gastrointestinal tract and kidney, were formalin-fixed, paraffin-embedded and stored until 2000, after which they were fresh-frozen. With regard to the surviving subjects, blood samples have been collected from 77 participants. Paraffin-embedded tissues, fresh-frozen tissues or blood samples were therefore available for a total of 1110 subjects, who were then selected for ACE gene I/D genotyping. Among those, however, 170 subjects had samples not suitable for genotyping, and another three subjects were excluded because of missing data on smoking habits. Thus, 937 subjects, representing 58% of the original cohort, were included in the present analysis.

Risk factors


At baseline examination, information on smoking habits and alcohol intake was obtained using a standard questionnaire. Smoking habits were classified into three categories: never-, ex- and current-smoking. Subjects who had stopped smoking 1 year or more before the start of the study were classified as ex-smokers. Current smoking

was subdivided into a further three categories: 1–9, 10–19 and 20 or more cigarettes per day. Alcohol intake was classified as either habitual use or no use. Body mass index (kg/m²) was used as an indicator of obesity. Serum cholesterol level was determined using the Zak–Henly method following the modification described by Yoshikawa *et al.* (1960). Glucose intolerance was determined by an oral glucose tolerance test in subjects with glycosuria, as well as by obtaining the subjects’ medical history regarding diabetes (Arima *et al.*, 2003). Recumbent blood pressures were obtained four times and the average values of the last three measurements were used in the analyses.

ACE I/D genotyping

Extraction of DNA from blood samples and fresh-frozen tissue samples was performed as described by Lahiri and Nurnberger (1991) and Tsukada and Ikari (1995), respectively. The ACE I/D genotype was determined using the polymerase chain reaction method as described by Evans *et al.* (1994). In the case of paraffin-embedded tissues, DNA was extracted using an automatic nucleic acid isolation system (NA-2000; Kurabo Inc., Osaka, Japan) and the ACE I/D genotype was determined using the double polymerase chain reaction method, as described previously (Arima *et al.*, 2002). All tissue samples obtained were examined microscopically to determine the presence or absence of tumour tissue, and only tumour-free tissues were used for ACE I/D genotyping. The accuracy of these genotyping methods was demonstrated in a previous study (Arima *et al.*, 2002).

Fig. 1



Flow diagram of the selection of study subjects.

Follow-up survey

The outcome of interest in the cases analysed in the present investigation was death due to any malignant neoplasm ($n = 176$). The participants were followed prospectively from November 1961 to October 1993 by means of repeated health examinations, or by a daily monitoring system established by the study team and local physicians, or by members of the Division of Health and Welfare of the town. The diagnosis of death due to malignant neoplasm was made based on clinical history, laboratory data, radiographs such as fluoroscopy of the gastrointestinal tract, cholangiography, urography, angiography, computed tomography, ultrasonograms, scintigrams, surgical findings, histopathological findings and disease courses. Clinical diagnoses were corrected by autopsy findings when necessary.

Statistical analysis

Genotype frequencies were compared with the values predicted by the Hardy-Weinberg equilibrium using the chi-square test. The mortality rates from malignant neoplasm were estimated by the person-year approach and were compared using the Cox's proportional hazards model. Hazard ratios (HRs) and 95% confidence intervals

(CIs) of risk factors were also estimated using the Cox's proportional hazards model, in which significant interaction terms were included.

Ethical consideration

This study was conducted with the approval of the ethics committee of Kyushu University, and written informed consent was obtained from participants or from the families of each deceased participant.

Results

The baseline characteristics of our subjects are shown in Table 1. Mean age was 58 years, and 53% of the participants were women. The frequency of ACE genotypes was 38% for II, 49% for ID, and 13% for DD. This distribution was in the range of the Hardy-Weinberg equilibrium (chi-square, 1.7; df, 2; $P = 0.6$) and was similar to those found in previous studies on Japanese populations (Higaki *et al.*, 2000). Forty-four per cent of the subjects were smoking at the time of the baseline.

During the follow-up period, 176 subjects died of malignant neoplasm. The effects of smoking status on fatal cancer are shown in Table 2. Although ex-smoker status was not clearly associated with cancer deaths, mortality rates due to cancer increased significantly with increasing current smoking levels. These results were substantially unchanged even after controlling for age, sex, ACE genotype, alcohol intake, body mass index, glucose intolerance, serum total cholesterol and systolic blood pressure. In the following analyses, subjects who never smoked and ex-smokers were combined as non-smokers, and current smokers were also combined into a single group regardless of the number of cigarettes smoked daily.

The effects of current smoking and other risk factors on fatal cancer are shown in Table 3. When adjustment was made for age and sex, current smoking was found to be a significant risk factor for cancer deaths; however, ACE genotype DD and other risk factors were not significantly associated with fatal cancer. In the multivariate analysis, age, current smoking and body mass index were found to

Table 1 Baseline characteristics of subjects ($n = 937$)

Characteristic	
Age, years (SD)	58 (11)
Women, n (%)	492 (53)
ACE genotype	
II, n (%)	360 (38)
ID, n (%)	459 (49)
DD, n (%)	118 (13)
Smoking habits	
Never-smokers, n (%)	493 (53)
Ex-smokers, n (%)	27 (3)
Current smokers	
1-9 cigarettes/day, n (%)	98 (10)
10-19 cigarettes/day, n (%)	208 (22)
≥ 20 cigarettes/day, n (%)	111 (12)
Alcohol intake, n (%)	331 (35)
Body mass index, kg/m ² (SD)	21.5 (2.6)
Glucose intolerance, n (%)	89 (9)
Serum total cholesterol, mmol/l (SD)	4.0 (0.9)
Systolic blood pressure, mmHg (SD)	136 (26)
Diastolic blood pressure, mmHg (SD)	78 (14)

SD, standard deviation; ACE, angiotensin I-converting enzyme; I, insertion; D, deletion.

Table 2 Mortality and age- and sex-adjusted and multivariate-adjusted hazard ratios with 95% confidence intervals for fatal cancer according to smoking status

	Smoking status (cigarettes per day)					P-value for trend
	Never	Ex	1-9	10-19	≥ 20	
Number of fatal cancers/person-years	68/10590	3/475	22/1610	44/4338	39/2314	
Crude mortality, per 1000 person-years	6.4	6.3	13.7	10.1	16.9	<0.0001
Age- and sex-adjusted HR (95% CI)	1.00 ^a	0.81 (0.25-2.62)	1.90 (1.16-3.12)	1.73 (1.06-2.83)	3.02 (1.79-5.08)	<0.0001
Multivariate-adjusted HR ^b (95% CI)	1.00 ^a	0.51 (0.12-2.14)	2.07 (1.25-3.43)	1.80 (1.08-3.00)	2.78 (1.62-4.78)	<0.0001

Never, never-smoker; Ex, ex-smoker; HR, hazard ratio; 95% CI, 95% confidence interval.

^aThis group served as the reference group.

^bAdjustment has been made for age, sex, angiotensin I-converting enzyme genotype, alcohol intake, body mass index, glucose intolerance, serum total cholesterol and systolic blood pressure.

be independent significant risk factors for cancer deaths. The interaction term between current smoking and ACE genotype DD was also significantly associated with fatal cancer (HR 3.31; 95% CI 1.15–9.51; $P = 0.03$), suggesting that this genotype significantly modified the effects of current smoking on the risk of death due to malignant neoplasm.

We further estimated the effects of current smoking on fatal cancer according to ACE genotype after controlling for age, sex, alcohol intake, body mass index, glucose intolerance, serum total cholesterol and systolic blood pressure (Table 4). Compared with non-smokers, current smokers had an increased risk of fatal cancer regardless of their ACE genotypes. However, the risk of fatal cancer in currently smoking subjects with the DD genotype (HR 4.51; 95% CI 1.38–14.79; $P = 0.01$) was twofold greater than that in subjects with genotype II (HR 2.00; 95% CI 1.11–3.59; $P = 0.02$) or ID (HR 2.24; 95% CI 1.20–4.18; $P = 0.01$). Among current smokers, subjects with genotype DD also showed a significantly greater risk of cancer death compared with subjects with genotypes II and ID combined (HR 1.77; 95% CI 1.04–3.00; $P = 0.03$).

Table 3 Age- and sex-adjusted and multivariate-adjusted hazard ratios with 95% confidence intervals of risk factors for fatal cancer

Variable	Age- and sex-adjusted HR ^a (95% CI)	Multivariate-adjusted HR ^a (95% CI)
Age, per 11-year increase	–	2.54 (2.09–3.10)
Sex, women versus men	–	0.72 (0.47–1.12)
Smoking habits, current versus non-smokers	2.06 (1.41–3.00)	1.91 (1.27–2.86)
ACE genotype, DD versus II and ID	1.20 (0.78–1.85)	0.53 (0.21–1.33)
Interaction (smoking habits × ACE genotype), yes versus no	–	3.31 (1.15–9.51)
Alcohol intake, yes versus no	0.91 (0.63–1.30)	0.96 (0.66–1.38)
Body mass index, per 2.6 kg/m ² increase	1.13 (0.98–1.32)	1.19 (1.02–1.40)
Glucose intolerance, yes versus no	1.25 (0.77–2.03)	1.19 (0.71–1.98)
Serum total cholesterol, per 0.9 mmol/l increase	0.97 (0.83–1.13)	0.95 (0.80–1.12)
Systolic blood pressure, per 26 mmHg increase	0.84 (0.71–1.00)	0.84 (0.70–1.01)

ACE, angiotensin I-converting enzyme; D, deletion; I, insertion; HR, hazard ratio; 95% CI, 95% confidence interval.

^aHazard ratios for continuous variables represent a difference of a standard deviation.

Table 4 Effects of current-smoking on fatal cancer according to angiotensin I-converting enzyme genotype

ACE genotype	Non-smoker			Current smoker			Adjusted HR ^a (95% CI)
	Person-years	N	Mortality	Person-years	N	Mortality	
II	4254	25	5.9	3181	40	12.6	2.00 (1.11–3.59)
ID	5463	39	7.1	4150	48	11.6	2.24 (1.20–4.18)
DD	1348	7	5.2	931	17	18.3	4.51 (1.38–14.79)

ACE, angiotensin I-converting enzyme; D, deletion; I, insertion; HR, hazard ratio; 95% CI, 95% confidence interval.

N: Number of fatal cancers. Mortality: per 1000 person-years.

^aAdjustment has been made for age, sex, alcohol intake, body mass index, glucose intolerance, serum total cholesterol and systolic blood pressure.

Discussion

In a prospective study of a general population, we found greater effects of current smoking on the instance of fatal cancer among subjects with ACE genotype DD compared with those with other genotypes. To the best of our knowledge, this is the first paper to suggest that ACE genotype DD enhances the association between smoking and the risk of cancer death. The strengths of the present study are that the causes of death were verified by autopsy in almost 80% of the deceased subjects, and that the tissue samples were stored for a long time. These circumstances provided us the opportunity to examine the long-term prospective contribution of smoking and ACE genotype to fatal cancer in a general population.

Previous studies have provided evidences linking the renin–angiotensin system with malignant neoplasm. Angiotensin II, which is a key peptide of the renin–angiotensin system, induces a mitogenic response in cancer cells (Muscella *et al.*, 2002), and blockade of the renin–angiotensin system reduces tumour growth (Volpert *et al.*, 1996; Small *et al.*, 1997; Fujita *et al.*, 2002), angiogenesis (Volpert *et al.*, 1996; Fujita *et al.*, 2002) and metastasis (Fujita *et al.*, 2002). The activities of the renin–angiotensin system are determined by genetic factors as well as by environmental ones. Plasma levels of ACE, which generates angiotensin II, are highly genetically determined, and a substantial proportion of interindividual variability is determined by the presence (I) or absence (D) of a 287-bp *Alu* sequence in intron 16 of the ACE gene (Rigat *et al.*, 1990). The D allele leads to higher expression of ACE mRNA than the I allele (Suehiro *et al.*, 2004), and therefore the DD genotype induces the highest circulating ACE levels and enhances the renin–angiotensin system (Rigat *et al.*, 1990). Through these mechanisms, ACE genotype DD may advance carcinogenesis.

The development of cancer is a multistep process, which is generally described as involving three steps: initiation, promotion and progression. Smoking is believed to be largely involved in the initiation and promotion steps of carcinogenesis (Suzuki *et al.*, 1992; Denissenko *et al.*, 1996; Pryor, 1997), while ACE genotype DD might be involved in the progression step (Volpert *et al.*, 1996;

Small *et al.*, 1997; Fujita *et al.*, 2002; Muscella *et al.*, 2002). The combination of smoking and the DD genotype has the potential to accelerate all steps of carcinogenesis and then to increase the risk of fatal cancer. Smoking has also been shown to increase plasma renin activity (Laustiola *et al.*, 1988). Elevated plasma renin activity (Laustiola *et al.*, 1988) together with elevated ACE levels (Rigat *et al.*, 1990) might accelerate the production of angiotensin II and thereby advance carcinogenesis, particularly among smokers with ACE genotype DD.

With regard to clinical studies using ACE inhibitors, Lever *et al.* (1998) report clinical evidence supporting the concept that long-term use of ACE inhibitors may protect against incident and fatal cancer, while other studies have shown no clear associations (Lindholm *et al.*, 2001; ALLHAT Officers and Coordinators, 2002). In these studies, however, smoking habits were more frequent (48%) among the subjects in Lever's report (Lever *et al.*, 1998) than among the subjects in the other two studies (9–22%) (Lindholm *et al.*, 2001; ALLHAT Officers and Coordinators, 2002). The present results indicate the possibility that ACE increases the risk of cancer primarily among smokers. Thus, protective effects of ACE inhibitors against cancer might have been detected by Lever *et al.* (1998). The different results regarding the effects of ACE genotype DD on malignant neoplasm reported in several other clinical studies (Cheon *et al.*, 2000; Usmani *et al.*, 2000; Haiman *et al.*, 2003; Hajek *et al.*, 2003; Koh *et al.*, 2003; Medeiros *et al.*, 2004) might also be due to differences in smoking status as well as in study design.

There are several potential limitations to the findings of the present study. The primary limitation is the small number of subjects in the study population; this makes further stratified analyses (e.g. by tumour sites) difficult. Thus, the generalizability of the present results may be somewhat limited. Nonetheless, we believe that the findings of our study represent an actual effect of ACE genotype on the association between smoking and cancer since we used a highly accurate method of determining all cases of cancer death. Another limitation is that our results might be biased by the exclusion of subjects whose genotype could not be determined. Among the 1606 subjects who were involved in the original cohort of 1621 participants and for whom data on smoking habits were available, 669 subjects without genotype information were younger than the 937 subjects with genotype information (54 versus 58 years, $P < 0.0001$) and a larger proportion of the population was female (62% versus 53%, $P = 0.0002$) at baseline. When adjustments were made for age and sex, subjects without information were more obese (body mass index 21.8 versus 21.5 kg/m², $P = 0.02$) and were more likely to use alcohol (41 versus 35%, $P = 0.03$). However, no significant differences were

observed between these groups in terms of other risk factors including current smoking (45% versus 44%, $P = 0.6$) and cancer mortality (8.0 versus 9.1 per 1000 person-years, $P = 0.2$). Finally, samples for genotyping were obtained from almost 80% of the deceased and our subject group is considered not to be biased due to deaths that occurred during the follow-up period. That is, this bias is not likely to have the potential to alter the present findings.

In conclusion, the present population-based prospective study suggests greater effects of current smoking on fatal cancer among subjects with ACE genotype DD than on those with genotype II or ID. These results raise the possibility that smoking cessation may have the greatest impact for reducing cancer mortality among people with ACE genotype DD. Further prospective studies of larger populations are needed to verify these findings.

Acknowledgements

This study was supported in part by grants from the Ministry of Education, Culture, Sports, Science, and Technology and the Ministry of Health, Labour, and Welfare of Japan.

References

- ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. *JAMA* **288**:2981–2997.
- Arima H, Kiyohara Y, Tanizaki Y, Nakabeppu Y, Kubo M, Kato I, *et al.* (2002). Detection of angiotensin-converting enzyme gene insertion/deletion polymorphism from paraffin-embedded tissues: the Hisayama Study. *Circ J* **66**:1034–1036.
- Arima H, Tanizaki Y, Kiyohara Y, Tsuchihashi T, Kato I, Kubo M, *et al.* (2003). Validity of the JNC VI recommendations for the management of hypertension in a general population of Japanese elderly: the Hisayama Study. *Arch Intern Med* **163**:361–366.
- Cheon KT, Choi KH, Lee HB, Park SK, Rhee YK, Lee YC (2000). Gene polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in patients with lung cancer. *Lung* **178**:351–360.
- Denissenko MF, Pao A, Tang M, Pfeifer GP (1996). Preferential formation of benz[*a*]pyrene adducts at lung cancer mutational hotspots in p53. *Science* **274**:430–432.
- Doll R, Peto R, Boreham J, Sutherland I (2004). Mortality in relation to smoking: 50 years' observations on male British doctors. *BMJ* **328**:1519–1528.
- Evans AE, Poirier O, Kee F, Lecarf L, McCrum E, Falconer T, *et al.* (1994). Polymorphisms of the angiotensin-converting-enzyme gene in subjects who die from coronary heart disease. *Q J Med* **87**:211–214.
- Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M (2002). Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. *Biochem Biophys Res Commun* **294**:441–447.
- Haiman CA, Henderson SO, Bretsky P, Kolonel LN, Henderson BE (2003). Genetic variation in angiotensin I-converting enzyme (ACE) and breast cancer risk: the multiethnic cohort. *Cancer Res* **63**:6984–6987.
- Hajek D, Tomiska M, Krahulcova E, Druckmuller M, Florianova M, Izakovicova-Holla L, *et al.* (2003). I/D ACE gene polymorphism in survival of leukemia patients: hypothesis and pilot study. *Med Hypotheses* **61**:80–85.
- Higaki J, Baba S, Katsuya T, Sato N, Ishikawa K, Mannami T, *et al.* (2000). Deletion allele of angiotensin-converting enzyme gene increases risk of essential hypertension in Japanese men: the Suita Study. *Circulation* **101**:2060–2065.
- Jee S, Samet J, Ohrr H, Kim J, Kim I (2004). Smoking and cancer risk in Korean men and women. *Cancer Causes Control* **15**:341–348.
- Katsuki S (1966). Epidemiological and clinicopathological study on cerebrovascular disease in Japan. *Prog Brain Res* **21**:64–89.

- Koh WP, Yuan JM, Sun CL, van den Berg D, Seow A, Lee HP, Yu MC (2003). Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. *Cancer Res* **63**:573–578.
- Lahiri DK, Nurnberger JI Jr (1991). A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. *Nucleic Acids Res* **19**:5444.
- Laustiola KE, Lassila R, Nurni AK (1988). Enhanced activation of the renin-angiotensin-aldosterone system in chronic cigarette smokers: a study of monozygotic twin pairs discordant for smoking. *Clin Pharmacol Ther* **44**:426–430.
- Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, et al. (1998). Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? *Lancet* **352**:179–184.
- Lindholm LH, Anderson H, Ekblom T, Hansson L, Lanke J, Dahlöf B, et al. (2001). Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. *Lancet* **358**:539–544.
- Medeiros R, Vasconcelos A, Costa S, Pinto D, Lobo F, Morais A, Oliveira J, Lopes C (2004). Linkage of angiotensin I-converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer. *J Pathol* **202**:330–335.
- Muscella A, Greco S, Elia MG, Storelli C, Marsigliante S (2002). Angiotensin II stimulation of Na⁺/K⁺ATPase activity and cell growth by calcium-independent pathway in MCF-7 breast cancer cells. *J Endocrinol* **173**:315–323.
- Pryor WA (1997). Cigarette smoke radicals and the role of free radicals in chemical carcinogenicity. *Environ Health Perspect* **105**:875–882.
- Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F (1990). An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. *J Clin Invest* **86**:1343–1346.
- Small W Jr., Molteni A, Kim YT, Taylor JM, Chen Z, Ward WF (1997). Captopril modulates hormone receptor concentration and inhibits proliferation of human mammary ductal carcinoma cells in culture. *Breast Cancer Res Treat* **44**:217–224.
- Suehiro T, Morita T, Inoue M, Kumon Y, Ikeda Y, Hashimoto K (2004). Increased amount of the angiotensin-converting enzyme (ACE) mRNA originating from the ACE allele with deletion. *Hum Genet* **115**:91–96.
- Suzuki H, Takahashi T, Kuroishi T, Suyama M, Ariyoshi Y, Ueda R (1992). p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. *Cancer Res* **52**:734–736.
- Tsukada T, Ikari J (1995). Rapid and simple method for preparation of DNA by SDS-Percol-Cloroform-GuSCN [in Japanese]. *Rinsho-Kagaku* **24**:65c.
- Usmani BA, Janeczko M, Shen R, Mazumdar M, Papandreou CN, Nanus DM (2000). Analysis of the insertion/deletion polymorphism of the human angiotensin converting enzyme (ACE) gene in patients with renal cancer. *Br J Cancer* **82**:550–552.
- Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, et al. (1996). Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. *J Clin Invest* **98**:671–679.
- World Health Organization (2002). *World health report 2002: reducing risk, promoting healthy life*. Geneva: World Health Organization.
- Yoshikawa H, Yoneyama Y, Kitamura M, Oyama H, Arimatu Y, Takahashi Z, et al. (1960). Study on the quantitative determination of serum total cholesterol by the ferric chloride method [in Japanese]. *Igaku-no-Ayumi* **33**:375–381.

Impact of Fasting Plasma Glucose Levels on Gastric Cancer Incidence in a General Japanese Population

The Hisayama Study

HAJIME YAMAGATA, MD¹
YUTAKA KIYOHARA, MD¹
SHOTARO NAKAMURA, MD¹
MICHIAKI KUBO, MD¹
YUMIHIRO TANIZAKI, MD¹

TAKAYUKI MATSUMOTO, MD¹
KEIICHI TANAKA, MD¹
ISAO KATO, MD¹
TOMOKO SHIROTA, MD²
MITSUO IIDA, MD¹

OBJECTIVE — Several studies have shown associations between diabetes and various types of cancer other than gastric cancer. The aim of this cohort study was to evaluate the impact of fasting plasma glucose (FPG) levels on gastric cancer occurrence.

RESEARCH DESIGN AND METHODS — A total of 2,466 Japanese subjects aged ≥ 40 years were stratified into three groups according to FPG tertiles (< 5.3 mmol/l, low FPG; 5.3–5.8 mmol/l, modest FPG; > 5.8 mmol/l, high FPG) and followed up prospectively for 9 years.

RESULTS — During the follow-up, 66 subjects experienced gastric cancer. In men, the age-adjusted incidences were significantly higher in the modest-FPG (7.0 per 1,000 person-years, $P < 0.05$) and high-FPG (7.2, $P < 0.05$) groups than in the low-FPG group (2.2). In women, the high-FPG group also had a significantly higher age-adjusted incidence of gastric cancer compared with the low-FPG group (2.5 vs. 0.8, $P < 0.05$). The multivariate analysis with Cox's proportional hazards model revealed that the risks of gastric cancer in the modest-FPG (relative risk [RR] 2.3 [95% CI 1.1–5.0]) and high-FPG (3.1 [1.5–6.4]) groups were significantly higher than that in the low-FPG group, even after adjusting for other comprehensive risk factors, including *Helicobacter pylori* status, smoking, and dietary factors. However, this FPG-cancer association was observed only among *H. pylori*-seropositive subjects.

CONCLUSIONS — Our findings suggest that a modest increase in FPG is a risk factor for gastric cancer and that hyperglycemia is a possible cofactor increasing the risk posed by *Helicobacter pylori* infection.

Diabetes Care 28:789–794, 2005

The Japanese population is characterized by a high morbidity from gastric cancer and a high prevalence of *Helicobacter pylori* infection, especially in middle-aged and elderly individuals (1).

We have previously reported a significant relationship between infection with *H. pylori* and a subsequent occurrence of gastric cancer for men in a general Japanese population (2). However, only a small

From the ¹Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; and the ²Department of Health Promotion, School of Health and Nutrition Sciences, Nakamura-Gakuen University, Fukuoka, Japan.

Address correspondence and reprint requests to Hajime Yamagata, MD, Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan. E-mail: yamagen@intmed2.med.kyushu-u.ac.jp.

Received for publication 29 July 2004 and accepted in revised form 10 January 2005.

Abbreviations: FPG, fasting plasma glucose.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

© 2005 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

percentage of people with *H. pylori* infection develop gastric cancer, indicating that *H. pylori* cannot be the only etiologic factor of gastric cancer; other cofactors must affect the relationship between *H. pylori* infection and the development of gastric cancer.

On the other hand, a possible association between diabetes and an increase in mortality from malignant neoplasm has been discussed for many years (3). Several prospective cohort studies have examined the associations between diabetes and total cancers (4–7). Among them, three studies have demonstrated that diabetes is associated with an excess risk for all cancers (4–6), while another study could not confirm a positive association between diabetes and total cancer (7). Several recent studies have shown associations between diabetes and cancer in the pancreas (8,9), liver (8,10), and large bowel (11,12). To our knowledge, none of the previous studies evaluated the impact of hyperglycemia on the development of gastric cancer.

In the present investigation, we prospectively examined the relationship between fasting plasma glucose (FPG) levels and gastric cancer occurrence in a general Japanese population, taking *H. pylori* infection as well as other comprehensive risk factors into consideration.

RESEARCH DESIGN AND METHODS

The Hisayama study is a prospective epidemiological study of ongoing cardiovascular disease and malignancy in Hisayama Town, a suburban community adjacent to Fukuoka City, a metropolitan area on Kyushu Island in Japan. The study design and characteristics of the subject population have been described in detail elsewhere (2,13,14). In 1988, 2,742 residents aged ≥ 40 years (80.1% of the total population in that age population) underwent a screening examination. After excluding 132 individuals with a prior history of gastrectomy or gastric cancer, 141 individuals who had

eaten breakfast on the day of the screening examination, and 3 individuals who died during the examination period, a total of 2,466 subjects were enrolled in the present study.

Follow-up survey

The population was followed up for 9 years, from December 1988 through November 1997, by repeated health check-ups every 1–2 years. For subjects who did not undergo regular check-ups or who moved out of the town, the health status was checked every year by mail or telephone. In addition, a daily monitoring system was established by the study team and local physicians or members of the Division of Health and Welfare of the town. To identify any occurrence of gastric cancer in the cohort, we reviewed radiographic, endoscopic, and biopsy records for the stomach at local clinics or general hospitals within and around Hisayama Town. We also checked all the records of the annual mass screenings for gastric cancer by means of barium X-ray examination. Further, to find any concealed gastric cancer, autopsy examinations were performed on 212 (79.1%) of a total of 268 subjects who died during the follow-up period. The diagnosis of gastric cancer was confirmed by histological examination of resected specimens obtained by gastrectomy, endoscopic mucosal resection, or autopsy.

During the follow-up period, only 1 subject was lost, and 71 gastric cancers were identified in 66 subjects (48 men and 18 women); 5 subjects (7.6%) each had two gastric cancers, and 2 concealed cases (3.0%) were diagnosed at autopsy. The time interval from the baseline screening to the diagnosis of gastric cancer ranged from 0.5 to 8.7 years (mean 5.0 years).

Laboratory testing and risk factor measurement

For the measurement of FPG levels, blood was drawn from an antecubital vein using vacutainer tubes with heparin, EDTA, and fluoridated sodium. The blood sampling was undertaken between 8:00 A.M. and 10:30 A.M. after an overnight fast of at least 12 h. Plasma glucose was determined by the glucose-oxidase method. Diabetes was determined by either a 75-g oral glucose tolerance test (1998 World Health Organization criteria), FPG levels (≥ 7.0 mmol/l), or a medical history of

diabetes. The numbers of subjects with diabetes diagnosed by each type of diagnosis were 294, 4, and 9, respectively. Based on the distribution of FPG levels, subjects were classified into tertile groups: low FPG (< 5.3 mmol/l), modest FPG (5.3–5.8 mmol/l), and high FPG (> 5.8 mmol/l).

Serum IgG antibodies to *H. pylori* were measured by means of a quantitative enzyme immunoassay using a commercial kit (HM-CAP; Enteric Products, Westbury, NY). The assay values were interpreted as positive, negative, or indeterminate, based on the manufacturer's instructions. Serum cholesterol levels were determined by an enzymatic auto-analyzer (TBA-80S; Toshiba, Tokyo, Japan). Height and weight were measured with the subject in light clothes without shoes, and the BMI (kg/m^2) was calculated. Dietary factors were obtained by a semiquantitative food frequency method that was previously validated in a prior study (15). A self-administered questionnaire concerning food intake over the previous year, which included 70 food items, was completed before the start of the study by each participant and was checked by experienced dietitians and nutritionists by showing food models of actual size in the survey. The average daily nutrient intakes, including total energy, total fat, salt, vitamin A, vitamin B₁, vitamin B₂, vitamin C, and dietary fibers, were calculated using the 4th revision of the Standard Tables of Food Composition in Japan (16), and the nutritional elements were adjusted for energy intake using the method of Willet and Stampfer (17). Information about smoking habits, alcohol intake, and history of peptic ulcer disease were obtained by means of a questionnaire administered to each subject, and the former two items were categorized as in current use or not in current use.

Statistical analysis

The SAS computer package (18) was used for all statistical analyses. Mean values of the possible risk factors were adjusted for age by the covariance method and were compared among tertile groups of FPG using Fisher's least significant difference method. The frequencies of risk factors were compared by the Mantel-Haenszel χ^2 test after adjusting for age by the direct method. The incidence of gastric cancer was calculated by the person-year method, and its differences among groups

with different FPG levels were analyzed by means of Cox's proportional hazards model (19). The risk factor-adjusted relative risks (RRs) were also estimated using Cox's proportional hazards model and are expressed together with 95% CIs. In the multivariate analysis, we used a stepwise method, setting the significance level for entry and keeping it at 0.1. Only 19 subjects who did not develop gastric cancer dropped out due to missing values in the covariates, while no case with gastric cancer dropped out of the analysis. For age adjustment, all study subjects were used as a standard population.

This study was conducted with the approval of the ethics committee of Kyushu University, and written informed consent for medical research was obtained from the study participants.

RESULTS— Table 1 compares the age-adjusted mean values or frequencies of possible risk factors for gastric cancer among the three FPG groups by sex. In men and women, the mean age increased significantly with an increase in FPG levels, and diabetes was found most frequently in the high-FPG group. Similarly, mean values of BMI and total cholesterol and frequency of alcohol intake in both sexes increased significantly with increases in FPG levels. The frequency of smoking habits in men decreased significantly with elevated FPG levels. The frequency of *H. pylori* infection and history of peptic ulcer disease and mean values of dietary factors were not found to be related to FPG levels in either sex.

As shown in Table 2, the age-adjusted incidence of gastric cancer of 5.6 per 1,000 person-years for men was significantly higher than that of 1.3 per 1,000 person-years for women. In men, the age-adjusted incidence was significantly higher in the modest-FPG (7.0, $P < 0.05$) and high-FPG (7.2, $P < 0.05$) groups than in the low-FPG (2.2) group. In women, the high-FPG group also had a significantly higher age-adjusted incidence of gastric cancer (2.5, $P < 0.05$) compared with that of the low-FPG group (0.8). The age- and sex-adjusted risks of gastric cancer in the modest-FPG (RR 2.3 [95% CI 1.1–5.1]) and high-FPG (3.0 [1.5–6.4]) groups were significantly higher than those in the low-FPG group (Fig. 1). These associations remained unchanged even after adjustment for age, sex, BMI, serum cholesterol, *H. pylori* se-

Table 1—Age-adjusted mean values or frequencies of risk factors for gastric cancer according to fasting plasma glucose levels by sex

Risk factors	Men			Women		
	Low FPG	Modest FPG	High FPG	Low FPG	Modest FPG	High FPG
n	278	326	424	551	484	403
Cases	5	19	24	3	4	11
Age (years)	56.5	56.2	59.1*†	57.0	58.5*	61.5*†
FPG (mmol/l)	5.01	5.55*	6.75*†	4.99	5.54*	6.74*†
Diabetes (%)	2.2	2.9	33.8*†	0.8	1.7	31.0*†
BMI (kg/m ²)	22.1	23.1*	23.6*†	22.4	23.2*	23.6*†
Total cholesterol (mmol/l)	4.97	5.08	5.27*†	5.52	5.46	5.71*†
Alcohol intake (%)	24.0	30.5	39.1*†	0.5	1.6	2.8*
Smoking habits (%)	55.4	48.5*	45.4*	6.1	7.2	7.2
<i>H. pylori</i> infection (%)	71.8	72.8	71.4	65.7	62.0	61.3
History of peptic ulcer disease (%)	27.0	21.3	22.1	9.9	9.6	8.0
Total energy intake (kcal/day)	1,826	1,901	1,863	1,541	1,525	1,510
Total fat intake (g/day)	44.3	43.4	43.8	49.4	49.4	49.4
Salt intake (g/day)	12.3	12.3	12.2	12.4	12.6	12.1
Vitamin A intake (IU/day)	2,392	2,465	2,369	2,893	2,922	2,836
Vitamin B ₁ intake (mg/day)	0.72	0.70	0.69	0.77	0.77	0.79
Vitamin B ₂ intake (mg/day)	1.03	1.01	1.03	1.15	1.16	1.18
Vitamin C intake (mg/day)	61.6	63.4	60.2	76.7	77.5	76.7
Dietary fiber intake (g/day)	9.2	9.1	8.9	11.0	11.1	11.2

* $P < 0.05$ vs. low FPG; † $P < 0.05$ vs. modest FPG.

repositivity, smoking habits, alcohol intake, history of peptic ulcer disease, and dietary factors, including intake of total energy, total fat, salt, vitamin A, vitamin B₁, vitamin B₂, vitamin C, and dietary fibers. In addition, we performed the same analysis with all subjects except for those who developed gastric cancer in the first 2 years of the follow-up period to decrease the influence of the concealed gastric cancers at baseline. As a result, the age- and sex-adjusted RR of gastric cancer was 2.2 (95% CI 0.9–4.9) in the modest-FPG group and 2.9 (1.3–6.3) in the high-FPG group. The magnitude of the cancer risk in the modest- and high-FPG groups was almost the same as that obtained in the analysis of all subjects, although no statistically significant difference was found in the modest-FPG group, probably due to the small number of cases.

The seroprevalence of *H. pylori* was 66.6% for all subjects, 77.3% for those with gastric cancer, and 66.3% for the subjects who did not develop gastric cancer. We then compared the risk of gastric cancer among FPG groups under stratification by *H. pylori* status (Fig. 2). Among *H. pylori*-positive subjects, the age- and sex-adjusted risks of gastric cancer were significantly higher in the modest-FPG (RR 3.5 [95% CI 1.3–9.5]) and high-FPG (4.2 [1.6–11.1]) groups than in the low-FPG group, whereas no such differences were found in *H. pylori*-negative subjects.

CONCLUSIONS— Our findings indicate a positive association between elevated FPG levels and gastric cancer incidence in men and women, an association that remains significant even after adjusting for other risk factors such as

age, sex, BMI, serum cholesterol, *H. pylori* seropositivity, smoking habits, alcohol intake, history of peptic ulcer disease, and dietary factors. The risk of gastric cancer was found to be increased not only in the high-FPG group, of which approximately one-third was diagnosed as diabetic, but also in the modest-FPG group, in which only a small number of subjects fulfilled the diagnostic criteria of diabetes. These results suggest that subjects with high FPG levels may have an increased risk of developing gastric cancer, even if they have not developed diabetes. In addition, a stratified analysis showed increased FPG levels to be an independent risk factor for gastric cancer only among *H. pylori*-seropositive subjects; no such risk was observed among *H. pylori*-seronegative subjects.

In this study, the age-adjusted inci-

Table 2—Age-adjusted incidence of gastric cancer according to FPG levels

	Men (n = 1,028)		Women (n = 1,438)		All (n = 2,466)	
	n	Incidence (95% CI)	n	Incidence (95% CI)	n	Incidence (95% CI)
Low FPG (<5.3 mmol/l)	5	2.2 (0.3–4.1)	4	0.8 (0.0–1.6)	9	1.4 (0.5–2.2)
Modest FPG (5.3–5.8 mmol/l)	19	7.0 (3.9–10.2)*	3	0.6 (–0.1 to 1.3)	22	3.3 (2.0–4.7)*
High FPG (>5.8 mmol/l)	24	7.2 (4.1–10.3)*	11	2.5 (1.0–4.1)*	35	4.5 (2.8–6.2)*
All	48	5.6 (4.0–7.3)	18	1.3 (0.7–1.9)†	66	3.1 (2.4–3.9)

Incidence rates are expressed per 1,000 person-years. * $P < 0.05$ vs. low FPG; † $P < 0.05$ vs. men.




Figure 1—Age- and sex-adjusted (□) and multivariate-adjusted (■) RR of gastric cancer of the modest-FPG (5.3–5.8 mmol/l) and high-FPG (>5.8 mmol/l) groups compared with that of the low-FPG (<5.3 mmol/l) group. In the multivariate analysis, the RR is adjusted for age, sex, BMI, serum cholesterol, *H. pylori* seropositivity, smoking habits, alcohol intake, history of peptic ulcer disease, and dietary factors (intake of total energy, total fat, salt, vitamin A, vitamin B₁, vitamin B₂, vitamin C, and dietary fibers) using stepwise Cox's proportional hazards model.

dence of gastric cancer was 5.6 per 1,000 person-years for men and 1.3 for women, which is higher than that found in previous studies in Japan (0.7–2.0 per 1,000 person-years for men and 0.3–0.7 for women) (20–23). This discrepancy seems to be due to differences in the study design as well as in the age structures or regions examined. The previous studies were registration studies, while ours was a prospective cohort study in which we carried out an intensive and accurate survey of gastric cancer, including autopsy examination of 79% of the deceased subjects to find any concealed gastric cancer. It is therefore supposed that our study results reflect the actual cancer incidence in the Japanese population.

The mechanisms for increased risk of gastric cancer in hyperglycemia remain obscure. One possible explanation is that hyperglycemia and its related conditions act directly as a carcinogenic factor. Dandona et al. (24) have demonstrated in a clinical study with diabetic subjects and healthy volunteers that diabetes is associated with increased production of reactive oxygen species and greater oxidative damage to DNA. In an experimental study, high glucose itself was shown to induce DNA damage (25). Thus, it is possible that increased production of reactive oxygen species or high glucose itself contributes to DNA damage, which may lead to mutational changes in oncogenes and tumor suppressor genes, and thereby to the development of gastric cancer.

Another possible explanation is that hyperinsulinemia is related to gastric carcinogenesis. Patients with hyperglycemia are prone to insulin resistance, which leads to higher levels of blood insulin.

McKeown-Eyssen (26) and Giovannucci (27,28) showed in epidemiological and experimental studies that hyperinsulinemia is involved in colonic carcinogenesis. These investigators independently hypothesized that well-specified risk factors for colorectal cancer, such as obesity, physical inactivity, alcohol consumption, or a typical western diet, contribute to insulin resistance. Ogiwara et al. (29) have demonstrated that insulin enhances the stimulatory effects of epidermal growth factor on the proliferation of cultured gastric epithelial cells obtained from the guinea pig. It can be speculated that an increase in cell proliferation predisposes the gastric mucosa to genetic or epigenetic alterations and, therefore, to carcinogenesis (30,31).

Finally, it is postulated that gastric cancer and hyperglycemia share common genetic or environmental risk factors. However, no common genetic background or common provisional risk factor other than age has been identified to date.

Furthermore, that hypothesis cannot be supported by our results; we failed to show any significant correlation of FPG levels with *H. pylori* status or with dietary factors. Further, although smoking habits have been presumed to be a risk factor for gastric cancer (32), the frequency of smoking habits in men was rather low in the high- and modest-FPG groups relative to that in the low-FPG group.

Based on numerous epidemiologic and experimental studies, *H. pylori* has been regarded to be a definite risk factor for gastric cancer (2,33). Although the precise pathogenetic role of *H. pylori* in gastric carcinogenesis remains unclear, it has been clarified that this organism contributes to modifications in epithelial cell proliferation (34,35), which may be the initiating event in a cascade culminating in the development of gastric cancer. However, an increased risk of gastric cancer by *H. pylori* infection notwithstanding, the majority of *H. pylori*-infected subjects do not develop gastric cancer. As such, *H. pylori* is not the absolute oncogenic factor for gastric cancer, and there must be other critical cofactors contributing to the risk posed by *H. pylori* infection. Our stratified analysis showed increased FPG levels to be a significant risk factor for gastric cancer only among *H. pylori*-seropositive subjects; this link was not observed among *H. pylori*-seronegative subjects. This result indicates that hyperglycemia is a possible cofactor increasing the risk posed by *H. pylori* infection. In a clinical study, Acbay et al. (36) demonstrated that *H. pylori* gastritis enhances glucose- and meal-stimulated insulin release, probably by increasing gastrin secretion. Thus, the enhanced effect of hyperglycemia on the *H. pylori*-cancer as-




Figure 2—Age- and sex-adjusted RR of gastric cancer of the modest (5.3–5.8 mmol/l) and high-FPG (>5.8 mmol/l) groups compared with that of the low-FPG (<5.3 mmol/l) group under stratification by *H. pylori* status. □, *H. pylori* seronegative; ■, *H. pylori* seropositive.

sociation may be explained partially by hyperinsulinemia. Another possible explanation for this phenomenon may be that hyperglycemia affects *H. pylori* and its infection status or stimulates its carcinogenic effects. However, the association between *H. pylori* infection and diabetes is controversial in the literature. A higher prevalence of *H. pylori* infection in diabetic than in control subjects has been reported in some studies (37,38), whereas other studies have found no association between *H. pylori* and diabetes (39,40). In this study, we found no significant correlation between FPG levels and *H. pylori* status. It may be speculated that increased reactive oxygen-related damage to DNA and genetic or epigenetic alterations in gastric mucosa induced by hyperglycemia or associated hyperinsulinemia encourage a modifying effect of *H. pylori* on epithelial cell proliferation, which may be the initial step in a cascade of gastric carcinogenesis. Given the range of findings, this hypothesis requires further consideration.

Several limitations of our study should be discussed. The primary limitation of our study, which is typical of most prospective studies, is that changes in other potentially confounding factors for the development of gastric cancer were not reassessed over time in our subjects. It is therefore possible that as a result of treatment for diabetes, greater modification of other risk factors occurred in diabetic than in nondiabetic subjects. In our subjects, however, the risk of gastric cancer was increased even in association with pre-diabetic hyperglycemia, which is not subject to medical treatment. In addition, the carcinogenic effects of risk factors usually continue for a long period (41–43). Thus, bias of this kind was considered to be small in the present study.

A second limitation is that an average follow-up time of 5 years does not account for the much longer latency or induction period of gastric cancer. Accordingly, we cannot eliminate the possibility that there were concealed gastric cancers that had already developed by the time of the baseline examination, though this limitation is a common problem for a large majority of other registration studies of gastric cancer. However, the prevalence of gastric cancer in healthy subjects has been found to be low (0.12%) in a nationwide mass screening in Japan (44). In addition, our analysis of

all subjects except for those who developed gastric cancer in the first 2 years of the follow-up period produced results similar to those obtained from our analysis of all subjects. We therefore believe that concealed cancers were rare at the baseline examination and that the influence of this bias is small.

The final limitation is that only a small number of gastric cancer cases developed in our cohort, indicating a high possibility of bias in the results. Nonetheless, we believe that the findings of our study represent an accurate incidence of gastric cancer and its association with hyperglycemia, since we performed the study using a highly accurate method for determining all gastric cancer cases.

In conclusion, we found the elevation of FPG levels to be a significant risk factor for gastric cancer in men and women. The contribution of FPG to the subsequent occurrence of gastric cancer was significant in *H. pylori*-seropositive subjects and not in *H. pylori*-seronegative subjects. These findings suggest that some interaction between hyperglycemia and *H. pylori* infection contributes to the development of gastric cancer or that hyperglycemia is a possible cofactor increasing the risk posed by *H. pylori* infection. Further study is necessary to clarify the pathogenetic role of hyperglycemia as well as of *H. pylori* infection and their interaction in gastric carcinogenesis.

Acknowledgments—This study was supported in part by a grant-in-aid for scientific research (C:13670370) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

References

1. The EUROGAST Study Group: An international association between *Helicobacter pylori* infection and gastric cancer. *Lancet* 341:1359–1362, 1993
2. Yamagata H, Kiyohara Y, Aoyagi K, Kato I, Iwamoto H, Nakayama K, Shimizu H, Tanizaki Y, Arima H, Shinohara N, Kondo H, Matsumoto T, Fujishima M: Impact of *Helicobacter pylori* infection on gastric cancer incidence in a general Japanese population: the Hisayama study. *Arch Int Med* 160:1962–1968, 2000
3. Kessler II: Cancer and diabetes mellitus: a review of the literature. *J Chron Dis* 23: 579–600, 1971
4. Steenland K, Nowlin S, Palu S: Cancer incidence in the National Health and Nutrition Survey I. Follow-up data: diabetes, cholesterol, pulse and physical activity. *Cancer Epidemiol Biomarkers Prev* 4:807–811, 1995
5. Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J: Post-load plasma glucose and cancer mortality in middle-aged men and women: 12-year follow-up findings of Chicago Heart Association Detection Project in Industry. *Am J Epidemiol* 131:254–262, 1990
6. Eschwege E, Charles MA, Simon D, Thibault N, Balkau B: From policemen to policies: what is the future for 2-h glucose? The Kelly West Lecture, 2000. *Diabetes Care* 24:1945–1950, 2001
7. Smith GD, Egger M, Shipley MJ, Marmot MG: Post-challenge glucose concentration, impaired glucose tolerance, diabetes, and cancer mortality in men. *Am J Epidemiol* 136:1110–1114, 1992
8. Wideroff L, Gridley G, Møllerkjær L, Chow WH, Linet M, Keihn S, Borch-Johnsen K, Olsen JH: Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. *J Natl Cancer Inst* 89:1360–1365, 1997
9. Everhart J, Wright D: Diabetes mellitus as a risk factor for pancreatic cancer: a meta-analysis. *JAMA* 273:1605–1609, 1995
10. Adami HO, Chow WH, Nyren O, Berne C, Linet MS, Ekblom A, Wolk A, McLaughlin JK, Fraumeni JF Jr: Excess risk of primary liver cancer in patient with diabetes mellitus. *J Natl Cancer Inst* 88: 1472–1477, 1996
11. Hu FB, Manson JE, Liu S, Hunter D, Colditz GA, Michels KB, Speizer FE, Giovannucci E: Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. *J Natl Cancer Inst* 91:542–547, 1999
12. Nilsen TL, Vatten LJ: Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. *Br J Cancer* 84:417–422, 2001
13. Katsuki S: Epidemiological and clinicopathological study on cerebrovascular disease in Japan. *Prog Brain Res* 21B:64–89, 1966
14. Ohmura T, Ueda K, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, Nomiya K, Ohmori S, Yoshitake T, Shinkawa A, Hasuo Y, Fujishima M: Prevalence of type 2 (non-insulin-dependent) diabetes mellitus and impaired glucose tolerance in the Japanese general population: the Hisayama study. *Diabetologia* 36:1198–1203, 1993
15. Shirota T, Yoshizumi E: Accuracy of nutritional survey using the simple method. *Jpn J Public Health* (in Japanese) 37:100–108, 1990
16. Resources Council of the Science and

- Technology Agency: *Standard Tables of Food Composition in Japan*. 4th ed. Tokyo, Ministry of Finance Printing Bureau, 1982 (in Japanese)
17. Willet W, Stampfer MJ: Total energy intake: implications for epidemiologic analysis. *Am J Epidemiol* 124:17–27, 1986
 18. SAS/STAT User's Guide. Version 6. Cary, NC, SAS Institute, 1989
 19. Cox DR: Regression models and life-tables. *J R Stat Soc (Series B)* 34:187–220, 1972
 20. The Research Group for Population-based Cancer Registration in Japan: Cancer incidence in Japan, 1985–89: re-estimation based on data from eight population-based cancer registries. *Jpn J Clin Oncol* 28:54–67, 1998
 21. Kaneko S, Yoshimura T: Time trend analysis of gastric cancer incidence in Japan by histological types, 1975–1989. *Br J Cancer* 84:400–405, 2001
 22. Lambert R, Guilloux A, Oshima A, Pompe-Kirn V, Bray F, Parkin M, Ajiki W, Tsukuma H: Incidence and mortality from stomach cancer in Japan, Slovenia and the USA. *Int J Cancer* 97:811–818, 2002
 23. Nishino Y, Suzuki Y, Ohmori K, Hozawa A, Ogawa K, Kuriyama S, Tsubono Y, Shibuya D, Tsuji I, Fukao A, Hisamichi S: Cancer incidence profiles in the Miyagi Cohort Study. *J Epidemiol* 14 (Suppl. 1): S7–S11, 2004
 24. Dandona P, Thusu K, Cook S, Snyder B, Makowski J, Armstrong D, Nicotera T: Oxidative damage to DNA in diabetes mellitus. *Lancet* 347:444–445, 1996
 25. Lorenzi M, Montisano DF, Toledo S, Barrioux A: High glucose induces DNA damage in cultured human endothelial cells. *J Clin Invest* 77:322–325, 1986
 26. McKeown-Eyssen G: Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? *Cancer Epidemiol Biomarkers Prev* 3:687–695, 1994
 27. Giovannucci E: Insulin and colon cancer. *Cancer Causes Control* 6:164–179, 1995
 28. Giovannucci E: Insulin, insulin-like growth factors and colon cancer: a review of the evidence. *J Nutr* 131 (11 Suppl.): 3109S–3120S, 2001
 29. Ogihara S, Yamada M, Saito T, Shono M, Rokutan K: Insulin potentiated mitogenic effect of epidermal growth factor on cultured guinea pig gastric mucous cells. *Am J Physiol* 271:G104–G112, 1996
 30. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE: Increased cell division as a cause of human cancer. *Cancer Res* 50:7415–7421, 1990
 31. Farber E: Cell proliferation as a major risk factor for cancer: a concept of doubtful validity. *Cancer Res* 55:3759–3762, 1995
 32. Inoue M, Tajima K, Yamamura Y, Hamajima N, Hirose K, Nakamura S, Kodera Y, Kito T, Tomimaga S: Influence of habitual smoking on gastric cancer by histologic subtype. *Int J Cancer* 81:39–43, 1999
 33. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ: *Helicobacter pylori* infection and the development of gastric cancer. *N Engl J Med* 345:784–789, 2001
 34. Anti M, Armuzzi A, Gasbarrini A, Gasbarrini G: Importance of changes in epithelial cell turnover during *Helicobacter pylori* infection in gastric carcinogenesis. *Gut* 43 (Suppl. 1):S27–S32, 1998
 35. Higashi H, Tsutsumi R, Muto S, Sugiyama T, Azuma T, Asaka M, Hatakeyama M: SHP-2 tyrosine phosphatase as an intracellular target of *Helicobacter pylori* CagA protein. *Science* 295:683–686, 2002
 36. Achay O, Celik AF, Gundogdu S: Does *Helicobacter pylori*-induced gastritis enhance food-stimulated insulin release? *Dig Dis Sci* 41:1327–1331, 1996
 37. Oldenburg B, Diepersloot RJ, Hoekstra JB: High seroprevalence of *Helicobacter pylori* in diabetes mellitus patients. *Dig Dis Sci* 41:458–461, 1996
 38. Gentile S, Turco S, Oliviero B, Torella R: The role of autonomic neuropathy as a risk factor of *Helicobacter pylori* infection in dyspeptic patients with type 2 diabetes mellitus. *Diabetes Res Clin Pract* 42: 41–48, 1998
 39. Gasbarrini A, Ojetti V, Pitocco D, De Luca A, Franceschi F, Candelli M, Sanz Torre E, Pola P, Ghirlanda G, Gasbarrini G: *Helicobacter pylori* infection in patients affected by insulin-dependent diabetes mellitus. *Eur J Gastroenterol Hepatol* 10:469–472, 1998
 40. Xia HH, Talley NJ, Kam EP, Young LJ, Hammer J, Horowitz M: *Helicobacter pylori* infection is not associated with diabetes mellitus, nor with upper gastrointestinal symptoms in diabetes mellitus. *Am J Gastroenterol* 96:1039–1046, 2001
 41. Inoue M, Tajima K, Hirose K, Kuroishi T, Gao CM, Kitoh T: Life-style and subsite of gastric cancer: joint effect of smoking and drinking habits. *Int J Cancer* 56:494–499, 1994
 42. Hansson LE, Nyren O, Bergstrom R, Wolk A, Lindgren A, Baron J, Adami HO: Diet and risk of gastric cancer: a population-based case-control study in Sweden. *Int J Cancer* 55:181–189, 1993
 43. Hansson LE, Baron J, Nyren O, Bergstrom R, Wolk A, Lindgren A, Adami HO: Early-life risk indicators of gastric cancer: a population-based case-control study in Sweden. *Int J Cancer* 57:32–37, 1994
 44. Hisamichi S: Screening for gastric cancer. *World J Surg* 13:31–37, 1989

Relationship Between C-Reactive Protein and Glucose Levels in Community-Dwelling Subjects Without Diabetes

The Hisayama Study

YASUFUMI DOI, MD
YUTAKA KIYOHARA, MD
MICHIAKI KUBO, MD
YUMIHIRO TANIZAKI, MD

KEN OKUBO, MD
TOSHIHARU NINOMIYA, MD
MASANORI IWASE, MD
MITSUO IIDA, MD

C-reactive protein (CRP), a marker of systemic inflammation, is emerging as an independent risk factor for cardiovascular disease (1,2). It has also been reported that serum CRP levels are elevated in patients with impaired glucose tolerance (IGT) (3) or diabetes (4). A few prospective studies have shown that increased CRP levels are an independent risk factor for future diabetes (5,6). Although these findings indicate that CRP levels in peripheral blood are closely associated with glucose levels, it remains unclear whether a relationship exists between CRP levels and plasma glucose levels in the pre-diabetic range. The purpose of the present study was to investigate the relationship between CRP concentrations and pre-diabetic plasma glucose levels in a general Japanese population.

RESEARCH DESIGN AND METHODS

A population-based prospective study of cardiovascular disease has been underway since 1961 in the town of Hisayama, Kyushu Island, Japan. In 1988, as a part of the study, a cross-sectional diabetes survey of Hisayama residents was conducted (7). Of all 3,227 residents aged 40–79 years in the town

registry, 2,587 (80.2%) consented to take part in a comprehensive assessment, including a fasting 75-g oral glucose tolerance test. After excluding 82 nonfasting participants, 15 of whom failed to complete the oral glucose tolerance test, 302 with diabetes based on the American Diabetes Association (ADA) criteria (8), and 61 without serum samples for the CRP measurement, the final study group included 2,127 subjects (882 men and 1,245 women).

Overnight fasting and 2-h postload plasma glucose levels were determined by the glucose-oxidase method, and serum insulin was determined by radioimmunoassay. Total cholesterol, HDL cholesterol, and triglycerides were all determined enzymatically. Serum specimens collected at the time of the CRP measurement were stored at -20°C until 2002. High-sensitivity CRP was analyzed using a modification of the Behring Latex-Enhanced CRP assay on the Behring Nephelometer Analyzer System with a 2% interassay coefficient of variation. Hypertension was defined as a systolic blood pressure ≥ 140 mmHg and/or a diastolic blood pressure ≥ 90 mmHg and/or current treatment with antihypertensive

agents. A questionnaire investigated smoking habits and alcohol intake, and both were classified as either currently or not currently habitual.

Because the distributions of CRP, fasting insulin, and triglycerides are skewed, these variables were natural log transformed for statistical analysis. The multivariate-adjusted CRP values were calculated by the covariance method and were compared by the Fisher's least significant difference method.

This study was conducted with the approval of the Ethics Committee of Kyushu University, and written informed consent was obtained from each participant.

RESULTS — The mean age was 57 years for both men and women. When the subjects were divided into three groups according to fasting plasma glucose levels, low (<5.6 mmol/l), modest (5.6–6.0 mmol/l), and high (6.1–6.9 mmol/l), the age- and sex-adjusted mean CRP levels significantly increased as the fasting glucose levels rose (0.41 mg/l in low, 0.49 mg/l in modest, and 0.62 mg/l in high fasting glucose level), and the differences between low and modest or high glucose levels were significant ($P < 0.01$). A similar pattern was observed for three 2-h postload glucose levels: low (<5.6 mmol/l), modest (5.6–7.7 mmol/l), and high (7.8–11.0 mmol/l). The age- and sex-adjusted CRP levels were 0.35 mg/l for low, 0.48 mg/l for modest, and 0.59 mg/l for the high postload glucose levels; the values were significantly higher for modest or high levels than for low levels ($P < 0.001$).

To clarify the existence of an independent relationship between each glucose level and CRP, we classified subjects into nine categories according to glucose levels measured at fasting and at 2-h postload and estimated mean CRP level in each category after adjustments for age, sex, fasting insulin, BMI, total cholesterol,

From the Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Address correspondence and reprint requests to Yasufumi Doi, MD, Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan. E-mail: doi@intmed2.med.kyushu-u.ac.jp.

Received for publication 13 December 2004 and accepted in revised form 24 January 2005.

Abbreviations: ADA, American Diabetes Association; CRP, C-reactive protein; IGT, impaired glucose tolerance.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

© 2005 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.




Figure 1—High-sensitivity C-reactive protein (CRP) levels according to fasting plasma glucose and 2-h postload glucose levels. Multivariate adjustments were made for age, sex, fasting insulin, BMI, total cholesterol, HDL cholesterol, triglycerides, hypertension, smoking habits, and alcohol intake. Parentheses indicate the number of subjects. * $P < 0.05$ vs. category with fasting plasma glucose <5.6 mmol/l and 2-h postload glucose <5.6 mmol/l.

HDL cholesterol, triglycerides, hypertension, smoking habits, and alcohol intake (Fig. 1). When compared with the category of fasting and postload glucose levels of <5.6 mmol/l, the adjusted CRP levels were significantly higher in the categories of IGT (high postload glucose levels, 7.8–11.0 mmol/l) and the modest postload glucose range (5.6–7.7 mmol/l), irrespective of fasting glucose levels.

CONCLUSIONS—The ADA recently proposed new criteria for diabetes and a lesser degree of impaired glucose regulation, although the criteria to diagnose diabetes and IGT remained as previously defined (8). However, the lower cut-off point defining impaired fasting glucose was reduced from ≥ 6.1 to ≥ 5.6 mmol/l. In our study, CRP progressively increased as fasting or postload glucose levels increased. These relationships did not show threshold effects, and CRP levels apparently rose even with the fasting glucose levels corresponding to the newly extended range of the impaired fasting glucose category (5.6–6.0 mmol/l) or with the postload glucose levels under the IGT category (5.6–7.7 mmol/l). These findings support the concept of the new ADA criteria for impaired fasting glucose, in which the expanded range of impaired

fasting glucose predicts future diabetes and cardiovascular disease (8). However, when analyzing fasting plasma glucose and 2-h postload glucose levels together, it is apparent that the elevated CRP levels in the new range, as well as in the range of impaired fasting glucose previously defined (6.1–6.9 mmol/l), are mainly due to elevated CRP concentrations according to 2-h postload glucose levels. These findings suggest that the glucose-CRP relationship is stronger for 2-h postload glucose levels than for fasting glucose levels. This hypothesis is in accordance with the findings of previous studies (9,10) showing the predominance of the effects of 2-h postload glucose levels on cardiovascular events.

A limitation is that CRP was measured by a long-term conserved serum at -20°C . It was however confirmed in the Reykjavik Study (11) that CRP concentrations were stable in preserved serum at this temperature for an average of 12 years.

To our knowledge, this is the first report to indicate a direct, positive relationship between CRP and pre-diabetic glucose levels across the normal range. Due to the cross-sectional design of the present study, however, we cannot infer from these results whether this relation-

ship is one of cause or effect. Prospective studies are needed to resolve this question.

References

- Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. *N Engl J Med* 336:973–979, 1997
- Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH: Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. *Circulation* 98:731–733, 1998
- Temelkova-Kurktschiev T, Henkel E, Koehler C, Karrei K, Hanefeld M: Subclinical inflammation in newly detected type II diabetes and impaired glucose tolerance. *Diabetologia* 45:151, 2002
- Ford ES: Body mass index, diabetes, and C-reactive protein among U.S. adults. *Diabetes Care* 22:1971–1977, 1999
- Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. *JAMA* 286:327–334, 2001
- Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, Tracy RP: The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. *Diabetes* 50:2384–2389, 2001
- Ohmura T, Ueda K, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, Nomiya K, Ohmori S, Yoshitake T, Shinkawa A, Hasegawa Y, Fujishima M: Prevalence of type 2 (non-insulin-dependent) diabetes mellitus and impaired glucose tolerance in the Japanese general population: the Hisayama Study. *Diabetologia* 36:1198–1203, 1993
- Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P: Follow-up report on the diagnosis of diabetes mellitus (Review). *Diabetes Care* 26:3160–3167, 2003
- Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. *Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe*. *Lancet* 354: 617–621, 1999
- Tominaga M, Eguchi H, Manaka H, Iga-

rashi K, Kato T, Sekikawa A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study.

Diabetes Care 22:920–924, 1999

11. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V: C-reactive

protein and other circulating markers of inflammation in the prediction of coronary heart disease. *N Engl J Med* 350: 1387–1397, 2004

Elevated C-Reactive Protein Is a Predictor of the Development of Diabetes in a General Japanese Population

The Hisayama Study

YASUFUMI DOI, MD
YUTAKA KIYOHARA, MD
MICHIAKI KUBO, MD
TOSHIHARU NINOMIYA, MD

YOSHIYUKI WAKUGAWA, MD
KOJI YONEMOTO, PHD
MASANORI IWASE, MD
MITSUO IIDA, MD

OBJECTIVE — We examined the association between high-sensitivity C-reactive protein (CRP) levels and the development of diabetes in a general Japanese population.

RESEARCH DESIGN AND METHODS — A total of 1,759 Japanese subjects, aged 40–79 years and without diabetes (according to American Diabetes Association fasting criteria), were stratified into three groups according to CRP tertiles by sex and followed up prospectively for a mean of 9.0 years.

RESULTS — During the follow-up, 131 subjects (67 men and 64 women) developed diabetes. In both sexes, the age-adjusted cumulative incidence of diabetes increased significantly as the tertiles of CRP levels increased. In multivariate analyses, the risk of developing diabetes was significantly higher in the highest CRP tertile than in the lowest after adjustment for a number of confounding factors (odds ratio 2.63 [95% CI 1.23–5.65] for men and 2.25 [1.01–5.01] for women). In stratified analyses, this CRP-diabetes association was stronger in subjects without obesity or other risk factors related to insulin resistance and in nondrinking subjects.

CONCLUSIONS — Our findings suggest that elevated CRP concentration is a significant predictor of diabetes in the general Japanese population, independent of obesity and insulin resistance.

Diabetes Care 28:2497–2500, 2005

In some cohort and nested case-control studies in Western countries, an elevated C-reactive protein (CRP) level has been an independent predictor of diabetes (1–10). Recent cross-sectional studies have also demonstrated clear associations of elevated serum CRP levels with obesity and insulin resistance (11–13). These findings suggest that the inflammatory state illustrated by elevated CRP concentrations is associated with hyperglycemia and diabetes through obesity or increased insulin resistance. However, epidemiological findings concerning this

issue are still controversial; several studies have reported a significant positive association between elevation in CRP levels and the future risk of diabetes even after adjustment for BMI (1,2,4,7,9,10), whereas in other studies (3,6) this association disappeared after adjustment for BMI.

Japanese are characterized by low BMI levels and low CRP concentrations in blood compared with Westerners (14). Moreover, there have been no reports on the relationship between CRP levels and the development of diabetes among gen-

eral populations in Japan. The aim of the present study is to examine the effects of serum CRP levels on the development of diabetes in a prospective study of a defined Japanese population, taking into account comprehensive risk factors.

RESEARCH DESIGN AND METHODS

Study population and follow-up survey

In 1988, a screening survey for the present study was performed in the Town of Hisayama in Japan. A total of 2,587 residents aged 40–79 years (80.2% of the total population of this age-group) participated in the baseline survey. The diabetes classification was based on the fasting criteria of the American Diabetes Association (15), i.e., subjects with fasting plasma glucose levels ≥ 7.0 mmol/l or those who were taking diabetes medications were considered diabetic.

After the exclusion of 80 subjects who had already eaten breakfast before the examination, 233 subjects with diabetes, and 67 subjects whose CRP concentrations could not be measured due to insufficient quantities of stored sera, the remaining 2,207 subjects (926 men and 1,281 women) were enrolled in the baseline examination. Among those, 1,759 subjects (694 men and 1,065 women) underwent follow-up examinations in 1993–1998 (follow-up rate 79.7%). We considered a subject to have developed diabetes when he/she met the above-mentioned baseline criteria. During this period, 131 subjects (67 men and 64 women) developed diabetes.

Laboratory measurements

Plasma glucose levels were determined by a glucose-oxidase method, and serum insulin was measured by radioimmunoassay. HbA_{1c} levels were measured by high-pressure liquid chromatography. Total cholesterol, HDL cholesterol, and triglycerides were all determined enzymatically. Serum specimens collected at the time of CRP measurement were stored at -20°C until used in 2002. High-sensitivity CRP

From the Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Address correspondence and reprint requests to Yasufumi Doi, MD, Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan. E-mail: doi@intmed2.med.kyushu-u.ac.jp.

Received for publication 14 February 2005 and accepted in revised form 1 July 2005.

Abbreviations: CRP, C-reactive protein.

A table elsewhere in this issue shows conventional and Systeme International (SI) units and conversion factors for many substances.

© 2005 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The Hisayama Study

concentrations were determined using a modification of the Behring latex-enhanced CRP assay. Sitting blood pressure was obtained three times and the average values used in the analyses. Hypertension was defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg and/or current treatment with antihypertensive agents. BMI (kilograms per meters squared) was used as an indicator of obesity.

Diabetes in first- or second-degree relatives indicated a family history of diabetes. Those subjects engaging in sports at least three times a week during their leisure time comprised a regular exercise group. Information on smoking habits and alcohol intake was used to classify subjects as having current habits or not.

Statistical analysis

Because the distributions of CRP, fasting insulin, and triglycerides were skewed, these variables were natural log transformed for statistical analyses. To analyze CRP levels as categorical variables, these levels were divided into tertiles by sex (0.05–0.28, 0.29–0.77, and 0.78–13.5 mg/l for men and 0.05–0.24, 0.25–0.57, and 0.58–5.78 mg/l for women). The age-adjusted cumulative incidence of diabetes was calculated by the direct method and compared by the Mantel-Haenszel χ^2 test using 10-year age-groupings. Age- and multivariate-adjusted odds ratios (ORs) and 95% CIs were calculated by logistic regression analysis. $P < 0.05$ was considered statistically significant in all analyses.

This study was conducted with the approval of the Ethics Committee of

Table 1—Characteristics of subjects by sex

	Men	Women
n	694	1,065
Age (years)	58 \pm 10	57 \pm 10
High-sensitivity CRP (mg/l)	0.49 (0.07–7.14)	0.36 (0.06–3.22)
Fasting plasma glucose (mmol/l)	5.6 \pm 0.5	5.5 \pm 0.5
HbA _{1c} (%)	5.5 \pm 0.5	5.4 \pm 0.5
Family history of diabetes (%)	9.3	7.3
Fasting insulin (pmol/l)	30.0 (18.0–72.0)	36.0 (18.0–72.0)
BMI (kg/m ²)	22.9 \pm 2.9	23.0 \pm 3.1
Total cholesterol (mmol/l)	5.10 \pm 1.04	5.57 \pm 1.05
HDL cholesterol (mmol/l)	1.26 \pm 0.30	1.35 \pm 0.29
Triglycerides (mmol/l)	1.25 (0.58–3.49)	1.02 (0.49–2.33)
Systolic blood pressure (mmHg)	131 \pm 19	130 \pm 20
Diastolic blood pressure (mmHg)	80 \pm 11	75 \pm 11
Hypertension (%)	41.5	32.7
Current drinking (%)	61.0	8.5
Current smoking (%)	47.6	5.4
Regular exercise (%)	16.1	4.9

Data are means \pm SD or medians (95% CI) unless otherwise indicated.

Kyushu University, and written informed consent was obtained from all participants.

RESULTS— The clinical characteristics of the subjects by sex are shown in Table 1. The mean age was 58 years for men and 57 years for women.

In both sexes, the age-adjusted cumulative incidence of diabetes increased significantly with elevating tertiles of baseline serum CRP concentrations. The incidences in the 3rd tertile for both sexes and in the 2nd tertile for men were significantly higher than in the 1st tertile (Fig. 1). As shown in Table 2, the risk of future diabetes in either sex was more than threefold higher in the 3rd tertile than in the 1st tertile after adjustment for age. These associations remained substantially

unchanged even after adjustment for the other confounding factors, including age, family history of diabetes, fasting insulin, BMI, total cholesterol, HDL cholesterol, triglycerides, systolic blood pressure, current drinking, current smoking, and physical activity (adjusted OR 2.63 [95% CI 1.23–5.65], $P = 0.014$, for men and 2.25 [1.01–5.01], $P = 0.049$, for women).

We next estimated the age- and sex-adjusted ORs and 95% CIs for the development of diabetes by an increment of 1 log CRP in men and women together according to the other risk factor levels (Table 3). Analyses were performed by dividing the subjects into three groups according to tertiles of BMI, triglycerides, and HDL cholesterol levels or into two




Figure 1—Age-adjusted cumulative incidence of diabetes according to tertiles of serum high-sensitivity CRP levels by sex.

Table 2—Age- or multivariate-adjusted ORs and 95% CIs for occurrence of diabetes according to tertiles of serum high-sensitivity CRP levels by sex

	High-sensitivity CRP level (mg/l)								
	Men				P for trend	Women			P for trend
	0.05–0.28	0.29–0.77	0.78–13.50			0.05–0.24	0.25–0.57	0.58–5.78	
Population at risk (n)	231	232	231		355	355	355		
Cases of diabetes (n)	11	26	30		10	21	33		
Age-adjusted OR (95% CI)	1 (referent)	2.67 (1.28–5.56)	3.23 (1.57–6.70)	0.002	1 (referent)	2.12 (0.98–4.58)	3.35 (1.60–7.03)	0.001	
Multivariate-adjusted OR (95% CI)	1 (referent)	1.96 (0.92–4.19)	2.63 (1.23–5.65)	0.014	1 (referent)	1.76 (0.80–3.87)	2.25 (1.01–5.01)	0.049	

Multivariate adjustment was made for age, family history of diabetes, fasting insulin, BMI, total cholesterol, HDL cholesterol, triglycerides, systolic blood pressure, current drinking, current smoking, and physical activity.

groups by hypertension status, current drinking, and current smoking. Significant positive associations between CRP levels and incident diabetes were observed among subjects in the 1st tertile of BMI, among subjects in the 1st and 2nd tertiles of triglycerides, among subjects of the 2nd and 3rd tertiles of HDL cholesterol, and among subjects without hypertension or current drinking. Significant associations were also observed in both smokers and nonsmokers. However, clear CRP-diabetes associations were not seen in the other categories of any risk factors.

CONCLUSIONS— We demonstrated in a prospective study of a general Japanese population that elevated CRP level is an independent predictor of diabetes for both sexes even after adjustment for comprehensive risk factors. In stratified analyses, the CRP-diabetes association was stronger in subjects without risk factors related to insulin resistance, such as obesity, dyslipidemia, and hypertension, and among nondrinkers, whereas the presence of a current smoking habit did not affect this association.

To our knowledge, this is the first report to indicate that the low-grade inflammatory state illustrated by increased CRP is an independent risk factor for developing diabetes in a general Japanese population. Similar findings were observed in a Japanese-American population (13) as well as in some other Western populations (5–12,14). Since Japanese Americans have a Western lifestyle, their findings cannot be generalized to Japanese living in Japan. Our subjects were thinner than those in previous reports (1–10). Our findings suggest that the subclinical inflammatory process has an important role in the development of di-

abetes in relatively lean Asian populations, as it does in Western populations.

Recent cross-sectional epidemiological data have demonstrated that elevated serum CRP levels are associated with obesity, insulin resistance, and glucose intolerance (11–13). These findings suggest that the inflammatory state affects glucose levels in blood and increases the risk of diabetes via obesity or insulin resistance. However, our study showed that the association between CRP levels and the development of diabetes is independent of serum insulin levels as well as BMI. These findings are in accord with those of sev-

eral other cohort studies (1,9). Additionally, our stratified analyses showed that the CRP-diabetes association was stronger particularly in individuals with low levels of risk factors related to insulin resistance. Therefore, a low-grade inflammatory state can be considered a risk factor for diabetes independent of obesity and insulin resistance, and unknown mediators are also thought to be involved in the development of diabetes.

In our subjects, the influence of CRP on the incidence of diabetes was stronger in nondrinkers than in drinkers. Some studies have shown that moderate alcohol

Table 3—Age- and sex-adjusted ORs and 95% CIs for occurrence of diabetes by an increment of 1 log high-sensitivity CRP in all subjects according to risk-factor levels

Risk factor	Population at risk (n)	Cases of diabetes (n)	Age- and sex-adjusted OR (95% CI)	P
BMI (kg/m ²)				
≤21.5	586	29	1.36 (1.05–1.75)	0.017
21.6–24.2	587	35	1.20 (0.92–1.57)	NS
≥24.3	586	67	1.25 (0.99–1.59)	NS
Triglycerides (mmol/l)				
≤0.88	587	30	1.30 (1.01–1.67)	0.042
0.89–1.34	582	29	1.50 (1.12–2.01)	0.007
≥1.35	590	72	1.16 (0.94–1.43)	NS
HDL cholesterol (mmol/l)				
≤1.14	572	49	1.04 (0.82–1.31)	NS
1.15–1.40	583	44	1.43 (1.13–1.81)	0.003
≥1.41	604	38	1.57 (1.20–2.07)	0.001
Hypertension				
Without	1,123	54	1.45 (1.18–1.77)	0.0003
With	636	77	1.16 (0.95–1.41)	NS
Current drinking				
Without	1,246	77	1.43 (1.20–1.71)	0.0001
With	513	54	1.14 (0.92–1.42)	NS
Current smoking				
Without	1,372	95	1.29 (1.09–1.53)	0.003
With	387	36	1.34 (1.04–1.72)	0.022

The Hisayama Study

consumption is associated with lower CRP concentrations (16,17). Additionally, recent cohort studies have revealed that moderate alcohol consumption reduced the risk of future type 2 diabetes (18,19). Therefore, the intake of alcohol may attenuate the influence of CRP on the development of diabetes.

A recent cohort study has reported a significant association between inflammation and future diabetes among non-smokers but not among smokers (8). In our subjects, however, an association between elevated CRP levels and incident diabetes was observed in both nonsmokers and smokers. This suggests that the CRP-diabetes association is independent of current smoking.

Several limitations of our study should be discussed. The primary limitation is that a diagnosis of diabetes was not based on a 75-g oral glucose tolerance test, but on a single reading of fasting glucose level, as was the case in other epidemiological studies (2,8,9). Subjects with diabetes having normal fasting glucose levels were misdiagnosed in our study. Additionally, some of the participants who were classified as having worsening fasting glucose status may not have been so categorized after repeated testing. These misclassifications should weaken the association found in this study. Therefore, the true association may be stronger than that shown in our findings. A secondary limitation is that CRP concentrations were measured in serum conserved for a long period at -20°C . However, the stability of CRP concentrations in serum preserved at this temperature for an average of 12 years was confirmed in the Reykjavik Study (20). The last limitation is that our study lacked information on drug use, which could affect serum CRP levels. It is known that several medications can alter CRP levels, including statins, ACE inhibitors, fibrates, niacin, thiazolidinedione, and estrogen/progesterone hormone (21). However, these medications were rarely used in our country in 1988. This suggests that such a bias does not invalidate the present findings.

In conclusion, we showed that subclinical elevation in CRP concentrations is an independent predictor of diabetes in a general Japanese population. CRP was an effective predictor of diabetes in individuals with the lowest BMI as well as in individuals without other risk factors related to insulin resistance. These findings add to the notion that low-grade in-

flammation is an important factor in the pathogenesis of type 2 diabetes. Further study is necessary to clarify the role of inflammation in the cascade to the development of diabetes.

References

1. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. *JAMA* 286:327–334, 2001
2. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, Tracy RP: The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. *Diabetes* 50:2384–2389, 2001
3. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. *Diabetes* 51:1131–1137, 2002
4. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O'Reilly DS, Packard CJ, Sattar N: C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. *Diabetes* 51:1596–1600, 2002
5. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM: Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. *Diabetes Care* 25:2016–2021, 2002
6. Thorand B, Lowel H, Schneider A, Kolb H, Meisinger C, Frohlich M, Koenig W: C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984–1998. *Arch Intern Med* 163:93–99, 2003
7. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF: Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC) Potsdam Study. *Diabetes* 52:812–817, 2003
8. Duncan BB, Schmidt MI, Pankow JS, Balantyne CM, Couper D, Vigo A, Hoogeveen R, Folsom AR, Heiss G: Low-grade systemic inflammation and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study. *Diabetes* 52:1799–1805, 2003
9. Nakanishi S, Yamane K, Kamei N, Okubo M, Kohno N: Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. *Diabetes Care* 26:2754–2757, 2003
10. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE: Inflammatory markers and risk of developing type 2 diabetes in women. *Diabetes* 53:693–700, 2004
11. Ford ES: Body mass index, diabetes, and C-reactive protein among U.S. adults. *Diabetes Care* 22:1971–1977, 1999
12. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). *Circulation* 102:42–47, 2000
13. Pradhan AD, Cook NR, Buring JE, Manson JE, Ridker PM: C-reactive protein is independently associated with fasting insulin in nondiabetic women. *Arterioscler Thromb Vasc Biol* 23:650–655, 2003
14. Yamada S, Gotoh T, Nakashima Y, Kayaba K, Ishikawa S, Nago N, Nakamura Y, Itoh Y, Kajii E: Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: Jichi Medical School Cohort Study. *Am J Epidemiol* 153:1183–1190, 2001
15. The Expert Committee on the Diagnosis and Classification: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 20:1183–1197, 1997
16. Albert MA, Glynn RJ, Ridker PM: Alcohol consumption and plasma concentration of C-reactive protein. *Circulation* 107:443–447, 2003
17. Imhof A, Froehlich M, Brenner H, Boeing H, Pepys MB, Koenig W: Effect of alcohol consumption on systemic markers of inflammation. *Lancet* 357:763–767, 2001
18. Nakanishi N, Suzuki K, Tatara K: Alcohol consumption and risk for development of impaired fasting glucose or type 2 diabetes in middle-aged Japanese men. *Diabetes Care* 26:48–54, 2003
19. Wei M, Gibbons LW, Mitchell TL, Kampert JB, Blair SN: Alcohol intake and incidence of type 2 diabetes in men. *Diabetes Care* 23:18–22, 2000
20. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. *N Engl J Med* 350:1387–1397, 2004
21. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation* 107:499–511, 2003

The 5-Year Incidence and Risk Factors for Age-Related Maculopathy in a General Japanese Population: The Hisayama Study

Miho Miyazaki,¹ Yutaka Kiyohara,² Ayako Yoshida,¹ Mitsuo Iida,² Yoshtaki Nose,³ and Tatsuro Ishibashi¹

PURPOSE. To estimate the 5-year incidence and risk factors for age-related maculopathy (ARM) in a representative older Japanese population.

METHODS. A population-based cohort study was conducted in 1998 on 1482 Hisayama residents aged 50 years or older, and 961 of these subjects attended the 5-year follow-up examinations in 2003. At both time points, the characteristics of ARM were determined by grading color fundus photographs according to the Wisconsin Age-Related Maculopathy Grading System. Using these cohort data, logistic regression analyses were performed to determine the risk factors for ARM. Nine possible risk factors were examined: age, sex, hypertension, diabetes, hyperlipidemia, smoking, alcohol intake, body mass index, and white blood cell count.

RESULTS. The 5-year incidence of early ARM was 8.5%, and that of late ARM was 0.8%. Men were found to have a significantly higher incidence of late ARM than did women. The incidence of both early and late ARM increased significantly with age. Multiple logistic regression analysis showed that age and smoking were significantly associated with early and late ARM.

CONCLUSIONS. The results suggest that the overall 5-year incidence of early ARM is 8.0% and that of late ARM is 0.8% in the general Japanese population and that higher age and smoking are relevant risk factors for early and late ARM in the Japanese. (*Invest Ophthalmol Vis Sci.* 2005;46:1907-1910) DOI:10.1167/iovs.04-0923

Age-related maculopathy (ARM) is a major cause of blindness and severe vision loss in older people in developed countries.¹⁻³ As the population ages in these countries, ARM will become an increasing public health problem. It is thus crucial that we identify the incidence and risk factors of the disease. Previous population-based studies have investigated several risk factors for ARM, including iris color,⁴ hypertension,⁵ atherosclerosis,⁶ a current smoking habit,⁷ and alcohol intake.⁸ In addition, we have reported the prevalence and risk factors for ARM in the representative Japanese community of Hisayama, by using cross-sectional data from the Hisayama study.⁹ However, although incidence data from the general population would be useful both for counseling patients and

understanding the natural course of disease, there has been no population-based study estimating the incidence of ARM in Japan.

The purpose of this study was to describe the 5-year incidence of early and late ARM in a representative Japanese population-based cohort. A further goal was to investigate the major factors that contribute to early and late ARM, by using the cohort data obtained.

METHODS

Study Population

The Hisayama Study is an ongoing, prospective population survey that has been conducted in the town of Hisayama since 1961. Hisayama is a suburb of Fukuoka City, which is on the island of Kyushu in the southern part of Japan. The population of the town is approximately 7500, a number that has remained stable for 40 years. According to the 1985 national census, the age distribution of the Hisayama population was almost identical with that of Japan as a whole.¹⁰ The occupations of the subjects were categorized into three types according to the Census for Labor and Products in Japan. Of the population aged 40 to 79 years in the town, 14.6% were engaged in a primary industry (agriculture, fishery, forestry), 29.8% in a secondary industry (mining, construction, manufacture), and 55.6% in a tertiary industry (commerce, restaurant, transport, communication, finance, insurance, supplier of electricity, gas or water, real estate business, service industry, and unclassified official business). The frequency distribution was very similar to that of all Japanese employees in the same age range: 14.5%, 33.4%, and 52.2%, respectively. As part of the follow-up survey, we performed a health examination, including an eye examination, of all Hisayama residents aged 50 years and older. The enrollment criteria, characteristics of the study population and overall design of this study have been described in detail in previous studies.⁹ The baseline eye examinations for the Hisayama Study were performed in 1998. Of the 3054 residents in that age group, 1844 (60.4%) consented to participate in the baseline eye examinations. Of these, 349 subjects underwent the health examination at home, whereas 13 subjects refused to participate in the ophthalmic examination. Ultimately, 1482 (48.5%) individuals (596 men and 886 women, 44.3% of the male population and 51.9% of the female population in that age group) underwent baseline eye examinations. Five-year follow-up eye examinations for the Hisayama Study were conducted in 2003. Of the original cohort, 961 (31.4%) persons took part in the examinations, of whom 3 had to be excluded due to ungradable photographs of either eye.

Ophthalmic Examination and Definition of Age-Related Maculopathy

The methods used for the baseline eye examinations have been described in detail elsewhere.⁹ Briefly, each participant underwent ophthalmic examinations after pupil dilation with 1.0% tropicamide and 10% phenylephrine. Fundus photographs (45°) were taken (model TRC NW-5 fundus camera; Topcon Corp., Tokyo, Japan), and 35-mm color transparencies were made using slide film (Sensia II Fujichrome; Fujifilm, Tokyo, Japan). In the 5-year follow-up eye examinations, fundus photographs (45°) were taken using a digital fundus camera

From the Departments of ¹Ophthalmology, ²Medicine and Clinical Science, and ³Medical Information Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Submitted for publication August 2, 2004; revised December 16, 2004, and January 31, 2005; accepted February 8, 2005.

Disclosure: M. Miyazaki, None; Y. Kiyohara, None; A. Yoshida, None; M. Iida, None; Y. Nose, None; T. Ishibashi, None

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Corresponding author: Miho Miyazaki, Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan; miho-m@info.med.kyushu-u.ac.jp.

(TRC NW-6SF; Topcon Corp.). In both examinations, we used a similar masked photographic grading technique based on the International ARM Epidemiologic Study Group grading protocol and the grids of the Wisconsin Age-Related Maculopathy Grading System.¹¹⁻¹³ The Wisconsin Age-Related Maculopathy Grading System grid was adapted to the magnification of the camera. This protocol divides ARM into early and late stages. Early-stage ARM was defined by the presence of drusen (soft distinct and soft indistinct) or retinal pigment epithelial (RPE) abnormalities (hyperpigmentation or hypopigmentation),¹³ within the grid in the absence of late ARM in either eye. Late-stage ARM was defined as the presence of neovascular age-related macular degeneration (AMD) or geographic atrophy (GA) involving the fovea. Neovascular AMD included serous or hemorrhagic detachment of the RPE or sensory retina, and the presence of subretinal or sub-RPE hemorrhages or subretinal fibrous scar tissue.¹⁵ GA was characterized by sharply edged, roughly round or oval areas of RPE hypopigmentation, with clearly visible choroidal vessels.¹⁵ The minimum area of GA was a circle 175 μm in diameter or larger. These definitions of early and late ARM were used in both the studies in Beaver Dam, Wisconsin, and Blue Mountains eye studies. In our study, two experienced graders (MM, TI), masked to the subject information, assessed the ARM. Inter- and intraobserver variability were analyzed by the κ statistic.¹⁴ The level of agreement between the graders was moderate (0.80-0.86) to substantial for most features.

Data Collection

Blood pressure was measured three times after the subject had rested for at least 5 minutes in the sitting position. The average of the three measurements was used for the analysis. Hypertension was defined as systolic blood pressure ≥ 140 mm Hg, diastolic blood pressure ≥ 90 mm Hg, or current use of antihypertensive medication. Blood samples were collected from the antecubital vein after an overnight fast. After taking the fasting blood specimen, a 75-g oral glucose tolerance test was performed with a 75-g glucose equivalent carbohydrate load (Trelan G; Shimizu Pharmaceutical Inc., Shimizu, Japan). Diabetes was defined as a fasting plasma glucose level ≥ 7.0 mM, a 2-hour postloading glucose level ≥ 11.1 mM, or a medical history of diabetes. The total cholesterol and serum triglyceride levels were determined enzymatically with an autoanalyzer (TBA-80S; Toshiba Inc., Tokyo, Japan), and hyperlipidemia was defined as a total cholesterol level ≥ 5.7 mM, serum triglyceride level ≥ 1.7 mM, or the current use of antihyperlipidemic medication. Information on alcohol consumption was obtained by interview, using a questionnaire that ascertained the usual weekly intake of alcoholic beverages over the previous several months. Subjects were classified as either light (< 34 g/d of ethanol) or heavy (≥ 34 g/d of ethanol) drinkers or as nondrinkers. Information on smoking habits was obtained with a standard questionnaire by trained interviewers at the initial examination, and the subjects were classified as either current or past habitual cigarette users or as nonsmokers. Body height and weight were measured in light clothing without shoes, and the body mass index (BMI) was calculated as the weight in kilograms divided by the height in meters squared. White blood cell counts (WBC) were determined with a counter (S1KS; Beckman-Coulter Inc., Brea, FL).

Statistical Methods

The 5-year incidences were calculated. Incident early ARM was defined by the appearance at follow-up of either soft drusen or retinal pigmentary abnormalities in either eye of persons in whom no early or late ARM was present at baseline. Incident late ARM was defined by the development at follow-up of neovascular AMD or GA in either eye of persons in whom no early or late ARM was present at baseline. We examined the relationships between the risk factors at baseline and the incidence of early and late ARM. We considered the following nine possible risk factors for ARM: age, sex, hypertension, diabetes, hyperlipidemia, smoking habit, alcohol intake, BMI, and WBC. Age, BMI, and WBC were treated as continuous variables and the others as categorical variables. Each categorical variable was coded either 1 or 0 depending

TABLE 1. Comparison of Baseline Characteristics between Participants Examined and Those Not Examined at the 5-Year Follow-up

Status at Baseline	Examined (<i>n</i> = 961)	Not Examined (<i>n</i> = 521)
Age (year)	64 \pm 8	68 \pm 10**
Sex (% men)	40.0	40.5
Early ARM (%)	17.3	15.6
Late ARM (%)	1.0	0.0
Hypertension (%)	46.7	56.4*
Diabetes (%)	11.9	17.9*
Hyperlipidemia (%)	52.2	53.5
Smoking habit (%)	32.9	38.0
Alcohol intake (%)	39.3	38.6
Body mass index (kg/m ²)	23.2 \pm 3.1	22.9 \pm 3.4
White blood cells ($\times 10^3/\text{mm}^3$)	5.7 \pm 1.5	5.9 \pm 1.5

Data are expressed as the mean \pm SD or percent.

* $P < 0.05$, ** $P < 0.01$, examined versus not examined.

on the presence or absence of the factor, respectively. Mean values were compared by the Student's *t*-test and frequencies by Pearson's χ^2 test. We estimated the age-adjusted and multivariate odds ratios (ORs) of each potential risk factor by using a stepwise logistic regression analysis. Only variables with $P < 0.05$ were entered into or allowed to remain in the stepwise multivariate regression analysis. Statistical analyses were performed on computer (SAS software; SAS Institute, Cary, NC).¹⁴ A two-sided $P < 0.05$ was considered statistically significant.

Ethical Considerations

This study was approved by the Human Ethics Review Committee of Kyushu University Graduate School of Medical Sciences, and was performed in accordance with the Declaration of Helsinki. Informed consent was obtained from all participants.

RESULTS

Table 1 shows the comparison of baseline characteristics between the participants who were examined and those who were not examined at the 5-year follow-up. Those who did not participate at the 5-year follow-up examination were more likely at baseline to be older (68 years vs. 64 years), to have hypertension (56.4% vs. 46.7%), and to have diabetes (17.9% vs. 11.9%). There were no significant differences between the two groups with respect to the presence of ARM or lifestyle habits.

The 5-year incidences of early and late ARM lesions by sex are shown in Table 2. One hundred sixty-six participants with early or late ARM were excluded at the baseline eye examination; in 67 (8.5%) participants incident early ARM developed during the 5-year follow-up period. The incidence of early ARM was slightly but not significantly higher in men than in women. The incidence of retinal pigmentary abnormalities was significantly higher in men than in women. After 13 participants with late ARM were excluded at the baseline eye examination, development of incident late ARM was recorded in 8 (0.8%) participants during the 5-year follow-up period. All participants who had incident late ARM had early ARM at baseline. Five of the eight participants who had late ARM had soft drusen at baseline, and three of the eight had pigmentary abnormalities at baseline. The incidence of late ARM was significantly higher in men than in women. After adjustment for age, men were found to have a significantly higher incidence of late ARM than were women (OR, 2.62; 95% confidence interval [CI], 1.18-5.82). The incidences of GA and neovascular AMD were significantly higher in men than in women.

Age-specific 5-year incidences of early and late age-related maculopathy by sex are shown in Table 3. The incidence of